How can onchocerciasis elimination in Africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector control

dc.contributor.authorVerver, S.
dc.contributor.authorWalker, M.
dc.contributor.authorKim, Y.E.
dc.contributor.authorFobi, G.
dc.contributor.authorTekle, A.H.
dc.contributor.authorZouré, H.G.M.
dc.contributor.authorWanji, S.
dc.contributor.authorBoakye, D.A.
dc.contributor.authorKuesel, A.C.
dc.contributor.authorDe Vlas, S.J.
dc.contributor.authorBoussinesq, M.
dc.contributor.authorBasáñez, M.-G.
dc.contributor.authorStolk, W.A.
dc.date.accessioned2019-02-05T08:39:13Z
dc.date.available2019-02-05T08:39:13Z
dc.date.issued2018-06
dc.description.abstractBackground. Great strides have been made toward onchocerciasis elimination by mass drug administration (MDA) of ivermectin. Focusing on MDA-eligible areas, we investigated where the elimination goal can be achieved by 2025 by continuation of current practice (annual MDA with ivermectin) and where intensification or additional vector control is required. We did not consider areas hypoendemic for onchocerciasis with loiasis coendemicity where MDA is contraindicated. Methods. We used 2 previously published mathematical models, ONCHOSIM and EPIONCHO, to simulate future trends in microfilarial prevalence for 80 different settings (defined by precontrol endemicity and past MDA frequency and coverage) under different future treatment scenarios (annual, biannual, or quarterly MDA with different treatment coverage through 2025, with or without vector control strategies), assessing for each strategy whether it eventually leads to elimination. Results. Areas with 40%-50% precontrol microfilarial prevalence and ≥10 years of annual MDA may achieve elimination with a further 7 years of annual MDA, if not achieved already, according to both models. For most areas with 70%-80% precontrol prevalence, ONCHOSIM predicts that either annual or biannual MDA is sufficient to achieve elimination by 2025, whereas EPIONCHO predicts that elimination will not be achieved even with complementary vector control. Conclusions. Whether elimination will be reached by 2025 depends on precontrol endemicity, control history, and strategies chosen from now until 2025. Biannual or quarterly MDA will accelerate progress toward elimination but cannot guarantee it by 2025 in high-endemicity areas. Long-term concomitant MDA and vector control for high-endemicity areas might be useful. © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society.en_US
dc.identifier.otherVolume 66, Issue suppl_4, Pages S267–S274
dc.identifier.otherhttps://doi.org/10.1093/cid/cix1137
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/27227
dc.language.isoenen_US
dc.publisherClinical Infectious Diseasesen_US
dc.subjectOnchocerciasisen_US
dc.subjectModelingen_US
dc.subjectMass drug administrationen_US
dc.subjectIvermectinen_US
dc.subjectEliminationen_US
dc.titleHow can onchocerciasis elimination in Africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector controlen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: